# A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Ascending Doses of ACT-1004-1239 in Healthy Male Subjects

> **NCT03869320** · PHASE1 · COMPLETED · sponsor: **Idorsia Pharmaceuticals Ltd.** · enrollment: 64 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** ACT-1004-1239
- **OTHER:** Placebo
- **DRUG:** ACT-1004-1239 (Food-effect subpart)
- **OTHER:** Placebo (Food-effect subpart)

## Key facts

- **NCT ID:** NCT03869320
- **Lead sponsor:** Idorsia Pharmaceuticals Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-03-25
- **Primary completion:** 2019-07-11
- **Final completion:** 2019-07-11
- **Target enrollment:** 64 (ACTUAL)
- **Last updated:** 2020-01-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03869320

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03869320, "A Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Ascending Doses of ACT-1004-1239 in Healthy Male Subjects". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03869320. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*